Detection of somatic variants in breast cancer specimens using the ClearSEEK PIK3CA Panel

Register to Watch Now

Learn how identifying PIK3CA variants provides a reliable tool for screening clinically relevant mutations in breast cancer tumors.

Leading experts, Dr. Werner Schroth and Dr. Alexander Sartori, discuss PIK3CA profiling using tumor biopsy specimens and highly sensitive analysis methods that provide accurate and reliable information for clinical trial evaluation and breast cancer management research.

Breast Cancer

Topics Include:

  • Utility of PIK3CA mutation profiling to inform breast cancer management.
  • High-sensitivity tumor biopsy analysis methods that can accurately determine the PIK3CA mutations information required for screening and evaluation.
  • Validation of a detection method that can reliably provide the sensitivity and specificity to accurately determine PIK3CA mutations for clinical decision-making.

Webinar Watch Now

Submit the form and you’ll be able to immediately access the webinar content.

Presented By:

Dr. Werner Schroth

Dr. Werner Schroth

Dr. Werner Schroth is a scientist in oncology research ‘pharmacogenomics and molecular profiling of breast cancer’, Institute of Clinical Pharmacology, at the Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart and University of Tübingen. Dr. Schroth received his PhD from the J.W.Goethe University, Frankfurt, Germany and completed post-doctoral studies at ITZ Hannover, Germany. He continued his career as a consultant and scientist-in-charge ‘autoimmune diagnostics’ at the Dermatological Institute, Offenbach, Germany. In his current work, Dr. Schroth focuses on pharmacogenomics of breast cancer including mitigating clinical resistance of hormone-receptor positive breast cancer treatment and the molecular profiling of breast tumors based on their transcriptome and somatic mutation landscape.
Dr. Alexander Sartori

Dr. Alexander Sartori

Dr. Alexander Sartori is a chemist with a PhD from the University of Kiel in cell biology; Alexander has 20 years’ experience in the life science industry and broad technical and application skills with a focus on oncology. For the past 10 years he has managed various collaborations and international consortia. In 2015 Alexander joined Agena Bioscience and in his current position he leads Agena’s Scientific Affairs oncology activities globally with a focus on liquid biopsy.